2 minute read
Taking science to Westminster Welsh biotech firm secures further investment for next-generation cancer therapies
Taking science to Westminster
One thing shared by the spectres of the COVID-19 pandemic and climate change is that science is broadly accepted as being important to understand how they work and to guide strategies that manage their impacts.
Both phenomena have placed science fairly, squarely and centre stage on the public’s radar and have got people talking. For those of us who are inspired and excited by science, this has been a good thing. There is a caveat, though. If science is to be useful as a beacon to navigate through the perils of pandemics and epidemics, we need to make sure that our leaders have access to and understand the facts that they need to help them carry out their public duties. At Biophys, this is exactly what we found ourselves doing in recent months. It was a real thrill to be asked to contribute to the Spring 2021 and Summer 2021 editions of the Science in Parliament journal – providing a piece about groundbreaking research into an emerging alternative explanation for Alzheimer’s disease progression and offering a view on commercialisation of late-stage science innovations.
We look forward to continuing to share science stories with and fly the flag of Welsh life sciences in the Parliamentary & Scientific Committee - All Party Parliamentary Group.
BiVictriX is a high-growth company and a future leader in cancer therapeutics. This transaction provides an exciting path ahead for both the firm and its investors.
Angelina Drljaca-Chandler and Catherine Golledge from Capital Law’s corporate team advised the Development Bank of Wales on the transaction.
Capital Law is a commercial law firm which works nationally and internationally with businesses of all sizes. It regularly provides corporate, commercial, employment and intellectual property legal advice to businesses in the life sciences sector.
www.biophys.co.uk
Welsh biotech firm secures further investment for nextgeneration cancer therapies
BiVictriX Therapeutics is working to deliver a broad pipeline of first-inclass therapeutics (named Bi-Cygni) which would enable potentially higher dosing and more aggressive tumour eradication in patients, without causing harmful side effects. Its lead programme is focused on treating Acute Myeloid Leukaemia – one of the most aggressive forms of blood cancer.
The company has announced that it is listing on the AIM market of the London Stock Exchange. The Development Bank of Wales, the existing lead investor in BiVictriX Therapeutics, will make an additional £500,000 share purchase and will remain the largest shareholder of the company following the listing. BiVictriX is proposing to raise £7.5m by way of placing a subscription of new ordinary shares as part of its IPO.
